Johnson, L., Shapiro, M., Stricker, R. B., Vendrow, J., Haddock, J., & Needell, D. (2020). Antibiotic Treatment Response in Chronic Lyme Disease: Why Do Some Patients Improve While Others Do Not? Healthcare, 8(4), 383. https://doi.org/10.3390/healthcare8040383
In 2020, the MyLymeData team partnered with researchers at the University of California, Los Angeles to better understand why some people with Lyme disease improve with treatment while others continue to struggle. Using information from more than 3,500 patients in the MyLymeData registry, researchers applied machine learning and traditional statistical methods to study real-world treatment outcomes.
Patients were grouped as Nonresponders, Low Responders, High Responders, or Well based on the amount of improvement they reported over time.
Better outcomes were most strongly linked to:
The findings highlight the importance of individualized, patient-centered care and suggest that some people with chronic Lyme disease may need longer treatment to achieve meaningful improvement.
Background. Treatment response varies among patients who remain ill after initial short-term antibiotic treatment, creating uncertainty about the most appropriate treatment approach and duration.
Methods. Researchers characterized Nonresponder, Low Responder, High Responder, and Well patient groups using health status, symptom severity, and reported improvement. Machine-learning and traditional statistical methods were then used to identify features most closely associated with better outcomes.
Results. Higher treatment response was most strongly associated with antibiotic treatment or combined antibiotic and alternative treatment, longer treatment duration, and oversight by a clinician whose practice focused on tick-borne diseases.
Conclusion. Treatment effects were highly variable. The findings support evaluating individual response and using personalized clinical judgment rather than relying exclusively on a standardized treatment approach.
The study explores why treatment outcomes differ among patients with chronic Lyme disease and identifies clinical and treatment features that may help predict meaningful improvement.
High Responders and Well patients reported better quality of life, greater overall improvement, and lower symptom burden. These groups were more likely to report antibiotic treatment, longer treatment duration, and care from clinicians who specialize in tick-borne diseases.
Patients vary substantially in their response to treatment. The results suggest that individualized care, adequate treatment duration, and ongoing assessment by experienced clinicians may be more useful than applying a single standardized approach to every patient.
The complete article contains the study’s full references, subgroup analyses, figures, tables, supplementary materials, and supporting calculations.
